Citius Oncology earnings were -$21.1M for the trailing 12 months ending Sep 30, 2024, with N/A growth year over year. The latest CTOR earnings report on Sep 30, 2024 announced Q3 2024 earnings of -$6.8M, up 42.7% from last quarter. For the last reported fiscal year 2024 ending Sep 30, 2024, CTOR reported annual earnings of -$21.1M, with 66.6% growth.
What were Citius Oncology's earnings last quarter?
Citius Oncology (NASDAQ: CTOR) reported Q3 2024 earnings per share (EPS) of -$0.10, up 25% year over year. Total CTOR earnings for the quarter were -$6.81 million. In the same quarter last year, Citius Oncology's earnings per share (EPS) was -$0.08.
As of the last Citius Oncology earnings report, Citius Oncology is currently losing money. Citius Oncology's net profit (also called net income) for the twelve months ending Sep 30, 2024 was -$21.15 million, a 66.56% increase year over year.
What was CTOR's earnings growth in the past year?
As of Citius Oncology's earnings date in Q1 2025, Citius Oncology's earnings has grown year over year. CTOR earnings in the past year totalled -$21.15 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.